Gain exposure to a diversified portfolio of companies
Early-stage gene editing companies: Early-stage companies developing gene editing therapies for a variety of diseases. If a company is successful in developing a new gene editing therapy that is approved by the FDA and reaches the market, it could generate significant revenue for investors.
Personalized cancer therapy companies. These therapies are tailored to the individual patient's genetic and other data, and they have the potential to be more effective and less toxic than traditional cancer treatments.
RNAi drug companies are all developing RNAi drugs. RNAi drugs have the potential to treat a wide range of diseases, including cancer, viral infections, and neurological disorders.
Cell and gene therapy companies are all developing cell and gene therapies for a variety of diseases. Cell and gene therapies are highly complex and expensive to develop and manufacture, but they have the potential to cure some diseases that are currently untreatable.
Looking into both early-stage and more established companies that are developing or commercializing new drugs and technologies